Kim Kuypers
Associate Professor of Psychopharmacology
Data updated
Research Footprint
Kim Kuypers appears in 54 tracked papers (2005–2026), most studied alongside Psilocybin, LSD and MDMA, across Depressive Disorders, Microdosing and Healthy Volunteers.
Most-cited paper: Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin (258 citations).
Frequent co-authors: Johannes Ramaekers, Nathalie Mason and Eline Theunissen.
Background & Research
Kim P. C. Kuypers is an Associate Professor at Maastricht University, specialising in the psychopharmacological properties of psychedelics and their applications in mental health. Her research extensively explores the impacts of various psychedelics, including lysergic acid diethylamide (LSD), 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), and MDMA, on behaviour and psychological wellbeing. Noteworthy contributions include studies demonstrating the effects of microdosing psychedelics on pain perception and life satisfaction, as well as investigating the drug-induced alterations in cognitive functions. Additionally, she has developed innovative research paradigms to deepen the understanding of psychedelic use motives and experienced effects, marking significant advancements in the scientific study of psychedelics.
Key Impact
Kuypers is a leading figure in psychedelic research, particularly in understanding the effects of psychedelics on pain perception and mental health.
Collaboration Network
54 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Kim Kuypers is associated with.
Maastricht University
academicAssociate Professor
While Maastricht University may not have a single dedicated psychedelic research group, various researchers at the university are investigating the effects of psychedelics. Early research exploring psychedelics at Maastricht focused on the dangers of MDMA. Now, research into the effects of microdosing is being led by Dr Kim Kuypers. Other research ongoing at the university is investigating cannabis as well as novel psychoactive substances (NPS). Maastricht is collaborating on research with the Beckley Foundation as well as Silo Pharma.
View stakeholder →Clerkenwell Health
UK psychedelic and CNS trial infrastructure provider with specialist trial sites, sponsor-facing psychiatric research support, recruitment pathways, and therapist-related trial expertise.
View stakeholder →